Panel Discussion: What challenges occurred during the co-development of the therapy with the companion diagnostic?
Time: 6:50 pm
day: Agilent
Details:
• Challenges to align timelines of clinical program and CDx program (fast transition from phase 1 study to registrations study, orphan drug designation with accelerated approval, etc.)
• Difficulty of sample procurement in the context of rare disease
• How does this launch impact the patients with synovial sarcoma?
• What are some of the considerations for commercializing a test for a rare disease?
